IL-23 Inhibitors Show Highest Drug Survival in Psoriasis

TOPLINE: Interleukin (IL)-23p19 inhibitors guselkumab and risankizumab demonstrated the highest drug survival for effectiveness and safety comparable with ustekinumab over 2 years, exceeding that of all other biologics. IL-17 receptor inhibitor brodalumab showed comparable effectiveness and safety with adalimumab and secukinumab. METHODOLOGY: Researchers conducted a cohort study using data from the British Association of Dermatologists …